MADISON -
The Riskguard test provides an individualized patient report that includes gene specific and familial risks using a simple blood or saliva sample for 10 common cancers, including colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine.
'Riskguard is a genetic test that can help patients understand their risk of developing certain cancers to inform screening, treatment and risks to other family members,' said
For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients. The Riskguard test also helps inform the risk stratification for patients who have a family history of cancer by identifying changes in cancer-associated genes. These actionable results help health care providers better understand their patients' risk level and management options, leading to more personalized care.
'Recently updated guidelines now recommend germline mutation testing for patients with breast cancer. We are proud to add the Riskguard test to our growing portfolio of innovative offerings - including the Oncotype DX and OncoExTra tests - that help improve outcomes,[1],2 across the cancer-care continuum,' said
The Precision Oncology commercial team will bring the Riskguard test to health care professionals. Most oncologists in the
The Riskguard test is a multi-cancer multigene panel that provides a report on variants in genes that are actionable and are included in an easy-to-understand report with potential care options to support treatment discussions.
As new relevant data becomes available about genes, cancer risk or medical management,
The Riskguard test and its performance characteristics are validated by
About Exact Sciences Precision Oncology portfolio
Exact Sciences Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX Breast Recurrence Score test is recognized as a standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive test of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive molecular tests available to patients today.
About
A leading provider of cancer screening and diagnostic tests,
Forward-Looking Statements
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the commercialization of the Riskguard test; the performance characteristics and clinical utility and the market acceptance and commercial success of the Riskguard test. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the
Contact:
Email: gpedroza@exactsciences.com
Tel: 949-468-7854
(C) 2024 Electronic News Publishing, source